Cardiovascular Events and Mortality in White Coat Hypertension: A Systematic Review and Meta-analysis.

Background: The long-term cardiovascular risk of isolated elevated office blood pressure (BP) is unclear.

Purpose: To summarize the risk for cardiovascular events and all-cause mortality associated with untreated white coat hypertension (WCH) and treated white coat effect (WCE).

Data Sources: PubMed and EMBASE, without language restriction, from inception to December 2018.

Resistant Hypertension and Renal Nerve Denervation.

Patients with resistant hypertension are a subgroup of the hypertensive population that are at even greater risk of cardiovascular outcomes. Therapeutic options for these patients are limited to antihypertensive medications. However, renal denervation (RDN) is a novel nonpharmacologic intervention that involves a catheter-based ablation of the sympathetic nerves within the renal artery wall.

Catheter-based Renal Artery Denervation for Resistant Hypertension: Promise Unfulfilled or Unsettled?

Resistant hypertension affects approximately 10-15 % of the hypertensive population and is associated with an increased occurrence of adverse cardiovascular outcomes. Recently, renal denervation (RDN) has emerged as a novel, non-pharmacologic therapy for resistant hypertension that is designed to ablate the sympathetic nerves distributed around the renal arteries, thus diminishing sympathetic nervous system activity and its influence on hypertension. RDN appeared to have a powerful BP-lowering effect in early clinical trials.

Antihypertensive Medications in End-Stage Renal Disease.

Hypertension is almost universal in end-stage renal disease (ESRD) and contributes to the substantial cardiovascular (CV) morbidity and mortality observed in these patients. The management of blood pressure (BP) in ESRD is complicated by a number of factors, including missed dialysis treatments, intradialytic changes in BP, medication removal with dialysis, and poor correlation of BPs obtained in the dialysis unit with those at home and with CV outcomes. Control of extracellular volume with ultrafiltration and dietary sodium restriction represents the principal strategy to manage hypertension in ESRD, and antihypertensive medications are subsequently added if this strategy is inadequate.

Use of continuous positive airway pressure for sleep apnea in the treatment of hypertension.

Purpose Of Review: Obstructive sleep apnea (OSA) and hypertension are highly prevalent and treatable conditions that often coexist and both contribute to an increased cardiovascular risk. The ability of continuous positive airway pressure (CPAP) to improve blood pressure in hypertensive patients with OSA is debated. This review highlights findings from recent studies that have investigated the impact of CPAP on blood pressure in patients with OSA.

What is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendations.

Hypertension is common in the elderly, and isolated systolic hypertension is responsible for the majority of hypertension in this population. Hypertension in the elderly can be attributed to numerous structural and functional changes to the vasculature that develop with advancing age. Increased systolic blood pressure is associated with adverse outcomes, including stroke, cardiovascular disease, and death.

Blood pressure control 1 year after referral to a hypertension specialist.

Hypertension is highly prevalent and remains poorly controlled. The purpose of this study was to evaluate blood pressure (BP) control in patients with uncontrolled hypertension 1 year after referral to a hypertension specialist. A retrospective chart review was performed on 158 patients evaluated by a single hypertension specialist between 2005 and 2010 at the Penn Hypertension Program.